Transthyretin Cardiac Amyloidosis | ATTR-CM for HCPs

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Log Out

Products

Order

Materials

Request Samples

Hospital Products

Vaccines

Patient Assistance

Pfizer Oncology Together

Pfizer RxPathways

Pfizer Dermatology Patient Access

Explore Content

Contact

About

Suspicion

Red flags

Suspicion tools

Diagnosis

Diagnostic testing

Diagnostic flow chart

Resources

Materials

Videos

Transthyretin cardiac amyloidosis*: an underdiagnosed, progressive, and infiltrative disease often overlooked as a cause of heart failure^1-3

*Also known as transthyretin amyloid cardiomyopathy (ATTR-CM).

Early, accurate diagnosis of ATTR cardiac amyloidosis can benefit patient care and may lead to improved outcomes.^3,4 Learn more about what to look for to raise suspicion of ATTR cardiac amyloidosis and how to diagnose the disease.

Disease overview & subtypes

Learn more

Recognizing the clinical signs

Learn more

Diagnosis of ATTR cardiac amyloidosis

Learn more

ATTR=transthyretin amyloidosis.

References:

Law S, Gillmore JD. When to suspect and how to approach a diagnosis of amyloidosis. Am J Med. 2022;135(suppl 1):S2-S8.

Kittleson M, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient with Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;S0735-1097(22)07423-X.

Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709-716.

Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-R1D-USA-1354